BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us
Archives
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • BioTech Events
  • BioTech Company Directory
  • Contact Us

Browsing Tag

Josh Bilenker

1 post

Josh Bilenker, MD, is a business executive and founder in the biotechnology space. He is currently the Chief Executive Officer of Treeline Biosciences which he founded along with Jeff Engelman M.D., Ph.D in September of 2021. Bilenker also serves in a Director role at Sana Biotechnology.

A self-described American healthcare optimist/realist, before launching Treeline, Dr. Josh Bilenker served as CEO of Loxo Oncology at Lilly, Eli Lilly and Company’s cancer research and development group.

Dr. Josh Bilenker joined the Eli Lily team in 2019 after the acquisition of Loxo Oncology, a company he founded and lead as CEO. Previously he worked as a venture capital investor in the biotechnology and healthcare spaces for Aisling Capital as well as serving as a US Food and Drug Administration (FDA) Medical Officer in the FDA Office of Oncologic Diseases (OOD).

His educational background includes the University of Pennsylvania where he studied and earned board certifications in the specialties of internal medicine and medical oncology. Dr. Josh Bilenker received his MD from The Johns Hopkins University School of Medicine along with his AB degree in English from Princeton University.

Former Lilly CEO Josh Bilenker & Former Novartis Head of Oncology Jeff Engelman Announce Treeline Biosciences
Jak Thomson
  • April 30, 2021

Biotech NewsEx-Lilly CEO Josh Bilenker & Ex-Novartis Head of Oncology Jeff Engelman Announce Treeline Biosciences

  • 2 minute read
Two powerhouse executives have joined forces to form a brand new cancer Biotech company. Josh Bilenker, M.D., and…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
  • CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
  • Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
  • SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
  • Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Comments
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • September 19, 2022
    Virios Therapeutics Stock Plunges 70% on Fibromyalgia Clinical Trial Failure Results
    Virios-Therapeutics-Stock-Plunges-70-on-Fibromyalgia-Clinical-Trial-Failure-Results
    • September 14, 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    CEL-SCI Multikine Phase 3 Data Highlighted at ESMO 2022
    • September 3, 2022
    Mayo Clinic, Hibiscus BioVentures, and Innoforce Announce Mayflower Cell and Gene Therapy Accelerator
    Mayo-Clinic-Gene-Accelerator
    • September 2, 2022
    SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
    SyneuRx CEO Interview Dr Emil Tsai BioTech Health X
    • August 1, 2022
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
    Krystal Biotech Announces FDA IND Acceptance for KB407 Cystic Fibrosis Clinical Trial
Recent Posts
  • ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    ImmunityBio Announces FDA Acceptance of BLA for N-803 Anktiva Bladder Cancer Drug
    • July 28, 2022
  • Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
    Brickell Biotech Regains Nasdaq Compliance Meeting Minimum Bid Price Requirement
    • July 22, 2022
  • Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    Merck Announces Failure in Keytruda Head and Neck Cancer Phase 3 Clinical Trial
    • July 20, 2022
Categories
  • BioTech CEO Interviews (4)
  • Biotech News (44)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by Code Supply Co.
  • Our Contributors
  • List of Modern Life Science Technologies
  • Contact Us
Back to top